Fredrik Thorén

1.2k total citations
16 papers, 289 citations indexed

About

Fredrik Thorén is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Fredrik Thorén has authored 16 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Fredrik Thorén's work include Diabetes Treatment and Management (16 papers), Diabetes Management and Research (14 papers) and Pancreatic function and diabetes (13 papers). Fredrik Thorén is often cited by papers focused on Diabetes Treatment and Management (16 papers), Diabetes Management and Research (14 papers) and Pancreatic function and diabetes (13 papers). Fredrik Thorén collaborates with scholars based in Sweden, United States and Belgium. Fredrik Thorén's co-authors include Paresh Dandona, Chantal Mathieu, Moshe Phillip, John Xu, Markus F. Scheerer, Nayyar Iqbal, Eiichi Araki, Marcus Lind, Enrico Repetto and Niki Arya and has published in prestigious journals such as PLoS ONE, Diabetes Care and Diabetes.

In The Last Decade

Fredrik Thorén

16 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fredrik Thorén Sweden 10 269 202 59 30 15 16 289
M Sedlak Austria 3 364 1.4× 204 1.0× 143 2.4× 60 2.0× 23 1.5× 6 399
Helen Partridge United Kingdom 7 308 1.1× 200 1.0× 51 0.9× 70 2.3× 10 0.7× 16 333
Kalyan Kumar Gangopadhyay India 9 121 0.4× 55 0.3× 20 0.3× 42 1.4× 25 1.7× 25 180
Keith Bowering Canada 6 336 1.2× 143 0.7× 31 0.5× 130 4.3× 7 0.5× 12 342
Liesbeth Van Huffel Belgium 7 350 1.3× 232 1.1× 221 3.7× 6 0.2× 12 0.8× 10 389
Carlos Trescolí Spain 7 182 0.7× 52 0.3× 21 0.4× 73 2.4× 9 0.6× 8 186
Sid McNulty United Kingdom 4 330 1.2× 89 0.4× 84 1.4× 93 3.1× 2 0.1× 13 361
Jenny Söderlund Finland 6 102 0.4× 27 0.1× 53 0.9× 18 0.6× 16 1.1× 7 159
Marianne C. Astor Norway 5 110 0.4× 147 0.7× 41 0.7× 17 0.6× 99 6.6× 10 196
Lauren Horton United States 4 183 0.7× 131 0.6× 92 1.6× 22 0.7× 1 0.1× 4 213

Countries citing papers authored by Fredrik Thorén

Since Specialization
Citations

This map shows the geographic impact of Fredrik Thorén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fredrik Thorén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fredrik Thorén more than expected).

Fields of papers citing papers by Fredrik Thorén

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fredrik Thorén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fredrik Thorén. The network helps show where Fredrik Thorén may publish in the future.

Co-authorship network of co-authors of Fredrik Thorén

This figure shows the co-authorship network connecting the top 25 collaborators of Fredrik Thorén. A scholar is included among the top collaborators of Fredrik Thorén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fredrik Thorén. Fredrik Thorén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Araki, Eiichi, Chantal Mathieu, Toshihiko Shiraiwa, et al.. (2021). Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT ‐2 study. Diabetes Obesity and Metabolism. 23(7). 1496–1504. 6 indexed citations
2.
Groop, Per‐Henrik, Paresh Dandona, Moshe Phillip, et al.. (2020). Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. The Lancet Diabetes & Endocrinology. 8(10). 845–854. 53 indexed citations
3.
Gordon, Jason, Thomas Danne, Christopher Edmonds, et al.. (2020). Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme. Diabetes Therapy. 11(5). 1135–1146. 3 indexed citations
4.
Phillip, Moshe, Chantal Mathieu, Marcus Lind, et al.. (2020). Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT ‐1 and ‐2 studies. Diabetes Obesity and Metabolism. 23(2). 549–560. 26 indexed citations
5.
Mathieu, Chantal, Paresh Dandona, Andreas L. Birkenfeld, et al.. (2020). Benefit/risk profile of dapagliflozin 5 mg in the DEPICT ‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m 2. Diabetes Obesity and Metabolism. 22(11). 2151–2160. 24 indexed citations
6.
Mathieu, Chantal, Gottfried Rudofsky, Moshe Phillip, et al.. (2020). Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT ‐2 study): 52‐week results from a randomized controlled trial. Diabetes Obesity and Metabolism. 22(9). 1516–1526. 43 indexed citations
7.
Mathieu, Chantal, Paresh Dandona, Moshe Phillip, et al.. (2019). SAT-LB025 Analysis of Benefit/Risk in the Subgroup of Patients with BMI of >=27 Kg/m2 in the Dapagliflozin DEPICT-1 and -2 Trials in Type 1 Diabetes. Journal of the Endocrine Society. 3(Supplement_1). 8 indexed citations
8.
Dandona, Paresh, Chantal Mathieu, Moshe Phillip, et al.. (2019). 1231-P: Dapagliflozin (DAPA) in Type 1 Diabetes (T1D): Pooled Outcomes from DEPICT-1 and -2. Diabetes. 68(Supplement_1). 2 indexed citations
9.
Araki, Eiichi, Hirotaka Watada, Yasuko Uchigata, et al.. (2019). Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial. Diabetes Obesity and Metabolism. 22(4). 540–548. 22 indexed citations
10.
Gordon, Jason, Thomas Danne, Hayley Bennett, et al.. (2019). 2355-PUB: Discontinuation of Dapagliflozin in DEPICT-1 and DEPICT-2 Led to Clinically Meaningful Increases in HbA1c and Body Weight. Diabetes. 68(Supplement_1). 1 indexed citations
11.
Mathieu, Chantal, Paresh Dandona, Moshe Phillip, et al.. (2019). Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2. Diabetes Care. 42(6). 1081–1087. 35 indexed citations
12.
Mathieu, Chantal, Paresh Dandona, Moshe Phillip, et al.. (2018). Glucose Variables in T1D Studies with Dapagliflozin—Pooled Analysis of Continuous Glucose Monitoring Data from DEPICT-1 and 2. Diabetes. 67(Supplement_1). 1 indexed citations
13.
Dandona, Paresh, Chantal Mathieu, Moshe Phillip, et al.. (2018). Long-Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—The DEPICT-1 Study. Diabetes. 67(Supplement_1). 10 indexed citations
14.
Watada, Hirotaka, Masanari Shiramoto, Shinya Ueda, et al.. (2018). Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. Diabetes Obesity and Metabolism. 21(4). 876–882. 18 indexed citations
15.
Mathieu, Chantal, Paresh Dandona, Pieter Gillard, et al.. (2018). Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—DEPICT-2 Study. Diabetes. 67(Supplement_1). 10 indexed citations
16.
Rydén, Anna, et al.. (2016). The Humanistic Burden of Type 1 Diabetes Mellitus in Europe: Examining Health Outcomes and the Role of Complications. PLoS ONE. 11(11). e0164977–e0164977. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M Sedlak Breakdown of academic impact, for papers by Helen Partridge Breakdown of academic impact, for papers by Kalyan Kumar Gangopadhyay Breakdown of academic impact, for papers by Keith Bowering Breakdown of academic impact, for papers by Liesbeth Van Huffel Breakdown of academic impact, for papers by Carlos Trescolí Breakdown of academic impact, for papers by Sid McNulty Breakdown of academic impact, for papers by Jenny Söderlund Breakdown of academic impact, for papers by Marianne C. Astor Breakdown of academic impact, for papers by Lauren Horton
Rankless by CCL
2026